utologous bone marrow (BM) transplantation has been used for support of high-dose chemotherapy in the treatment of various neoplastic diseases (1) . Under steady-state conditions, the majority of primitive hematopoietic stem/progenitor cells reside in the bone marrow, and only a low number of these cells can be isolated from the peripheral blood. However, additional peripheral blood progenitor cells (PBPC) and peripheral blood stem cells (PBSC) can be mobilized by treatment with myelosuppressive agents (2) , or growth factors (3, 4) . Recent studies have shown that PBPC and PBSC exhibit enhanced potential for engraftment as compared with BM transplantation (4, 5) .
Recently our group demonstrated that administration of recombinant human (rh)IL-7 to mice mobilized myeloid progenitor cells from the BM to the spleen(s) (6) , blood, and liver (7) . Administration of rhIb7 to irradiated mice also increased the number ofmegakaryocytes and immature granulocytes in the spleen in vivo (8) . In vitro rhIb7 enhanced CSF-induced myeloid colony formation from primitive Lin-Sca-1 + murine BM progenitor cells, without effecting proliferation of committed Lin-Sca-1-myeloid progenitors (9) . These findings, in addition to the well-known effects of II:7 on lymphopoiesis (10) , and the documented expression of receptors for II:7 on myeloid cells (11) , suggested that this cytokine also may play an important role in myelopoiesis. The present studies were performed to determine whether rhlL-7 could mobilize PBSC with long-term reconstitution potential in lethally irradiated recipients.
Materials and Methods
Mice. C57BL/6 (Ly 5.2) and their congenic C57BL/6-Ly 5.1 mice (12) were obtained from the Animal Production Area of the National Cancer Institute-Frederick Cancer Research and Development Center, maintained in a specific pathogen-free environment, and used between 8 and 10 wk of age.
Reagents. rhlb7 was purchased from PeproTech (Rocky Hill, NJ), and had asp act of 2 x 107 U/mg as measured by proliferation ofa murine pre-B cell line (IxN/A6). The endotoxin level was <0.1 ng/ml. Lyophilized material was diluted in citrate buffer, pH 6.0, to a concentration of 1 mg/ml. Mice received injections of rhlL-7 or diluent HBSS without Ca 2+, Mg ;+ and phenol red 
Enrichment and Purification of Pe@heral Blood Leukocytes (PBL).
Peripheral blood from C57BL/6-Ly 5.1 mice that had been treated with 5 #g of rhlL-7 or diluent twice daily for 7 d was collected by cardiac puncture and placed into EDTA-containing tubes. Blood was pooled by group, layered over Lymphocyte Separation Media gradients of 1.077-1.080 g/ml (Organon Teknika, Durham, NC) and centrifuged at 800 g for 20 rain at 20~ Low density (LD) PBL from the interface were collected, washed, resuspended in plain HBSS, and then used for transplantation.
Preparation of BM, Spleen Cells, and Thymocytes. BM from both femurs and tibiae, spleen cells, and thymocytes were isolated from recipient mice (6, 7, 13) and resuspended in HBSS plus 1% BSA (GIBCO/BRL, Bethesda, MD) for flow cytometric analysis (FCA). BM cells used for transplantation were resuspended in cold HBSS.
Transplantation. C57BL/6 (Ly 5.2) recipient mice were exposed to a total of 11.0 Gy 137Cesium irradiation (dose rate, 23.2 cGy/min) delivered in two equal doses of 5.5 Gy given 3 h apart. The CFU-S assay was performed by the i.v. injection of 2 x 10 s LD PBL or BM cells from rhlb7-treated or HBSS-treated C57BL/ 6-Ly 5.1 donor mice into irradiated recipients. On days 8 and 12 after transplantation, the number of macroscopically visible surface colonies (CFU-S) on fixed spleens was counted (14) . Longterm survival and reconstitution studies were done by injecting various numbers ofLD PBL or BM cells from rhlL-7-treated or HBSStreated C57BL/6-Ly 5.1 donors intravenously into lethally irradiated C57BL/6 (Ly 5.2) recipients.
Surface Phenotype Analysis. Hematopoietic reconstitution was determined by two-to three-color immunofluorescence labeling followed by FCA (6) . Donor-derived (Ly 5.1 +) or host-derived (Ly 5.2 +) cells were detected using the mAb clones A-20-1.7 or 104-2.1 (15), respectively, and developed with FITC-conjugated affanitypurified goat anti-mouse IgG2a (Fisher Scientific, Orangeburg, NY) or they were biotinylated and developed with Streptavidin-RED670 (GIBCO BRL). B-lineage cells and granulocytes were detected using PE-conjugated RA3-6B2 (B220) or PE-conjugated RB6-8C5, respectively (PharMingen, San Diego, CA). CD4 § or CD8 + T-lineage cells were detected using PE-conjugated GK 1.5 (L3T4) or biotin-conjugated 53-6.7 (Ly 2) developed with Streptavidin-RED670, respectively (Becton Dickinson, San Jose, CA). T cells were detected using 500A2 (CD3) as previously described (6).
Statistical Analysis. All statistical evaluations were performed using the computer software Instat ver. 2.02 or GraphPad Prism for Windows ver 1.0 (GraphPad Software, San Diego, CA). Statistically significant differences based on absolute numbers were determined by two-tailed, Student's t test (16) . Results from survival experiments were analyzed by log-rank nonparametric test and expressed as Kaplan-Meier survival curves. tion to its established ability to mobilize single-lineage CFU-c and multi-lineage CFU-granulocyte erythroid megakarocyte macrophage (GEMM) (7), IL7 potently mobilized primitive CFU-S from the BM to the blood.
Results and Discussion
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PBL Isolated from rhlL 7-treated Donors Rescue Lethally Irradiated Mice.
To determine if rhlb7 could mobilize pluripotent stem cells, lethally irradiated C57BL/6 (Ly 5.2) recipients were transplanted with various numbers of PBL from C57BL/ 6-Ly 5.1 donors that were pretreated with rhlL-7 (5 #g/twice daily). As shown in Fig. 2 A, 106 PBL obtained from rhlL-7-treated donors rescued 90% of the irradiated recipients, whereas the same number of PBL isolated from control donors produced no survivors. A higher number of PBL (5 x 106 and 1 x 107) transplanted from rhlL-7-treated donors rescued 100% of the recipients, whereas these cell doses of PBL from control mice were much less efficient (5 x 106, 10% and 1 x 107, 70%). These results demonstrated that PBL from rhIb7-treated mice were much more efficient in longterm rescue of irradiated recipients, suggesting the mobilization of pluripotent stem cells with long-term marrow repopulating activity.
PBL fwm Mice 7~eated with rMb 7 Contain Long-term Reconstituting Stem Cells that Repopulate all Leukocyte Lineages in
Lethally Irradiated Recipient Mice. To determine if the rescue of lethally irradiated recipients by rhlL-7 mobilized PBL was associated with reconstitution by stem/progenitors cells transplanted from donor mice, the percentage of donor (Ly 5.1 +) vs host (Ly 5.2 +) repopulation in BM, thymus, and spleen of surviving recipient mice was assessed by FCA at 3 (shortterm repopulation) and 6 mo (long-term repopulation). The analysis of data at 3 mo revealed that 107 PBL from rhlL-7-treated donors reconstituted BM, thymus, and spleen cellularity to the same degree as did 106 BM cells from control or rhlb7-treated donors ( Table 1) . Analysis of short-term host vs donor reconstitution in recipient mice transplanted with 107 PBL from rhlb7-treated donors (Fig. 3, 3 
MONTHS) demonstrated that the majority of the cells in
various organs were of donor origin (the percentage of donor Ly 5.1 + cells ranged from 89 to >99). These percentages were significantly (p <0.001) greater than those obtained from reconstitution by 107 PBL from control mice which showed only 8% donor reconstitution of the bone marrow and 5% donor reconstitution of the thymus in recipient mice. After 3 mo, reconstitution of the spleen with 107 PBL was somewhat better (27 _+ 8%), but was still significantly lower than the reconstitution achieved by 106 ~ <0.05) or 107 (p < 0.001) PBL from rhlb7-treated mice. Thus, the repopulation that occurred in the group that received 107 PBL from control donors was largely of recipient origin by 3 mo. The transfer of 106 PBL from rhlL-7-treated donors also resulted in better mean levels of percent donor repopulation than did 107 transferred normal PBL, but the variability was higher among the responding mice (Fig. 3, 3 
MONTHS).
Because the 3-mo survival assay is considered to be a good measurement for only short-term repopulating stem cells (17) , repopulation was also analyzed at 6 mo, which measures repopulation by totipotential stem cells. As shown in Table  1 , all of the recipients had considerable repopulation by 6 mo; however the reconstitution of the spleen by 107 PBL from control mice was significantly lower (p <0.05) when compared with PBL (107) from the rhlL-7-treated mice and BM from normal or rhlL-7-treated mice. The percentages of donor ceils in surviving mice at 6 mo were similar to those noted at 3 mo (Fig. 3) . The efficiency of overall donor-origin cell repopulation in some organs was less in mice that received 107 PBL from control mice versus those that received 107 PBL from rhlL-7-treated donors (BM, 4 + 1% vs 92 _+ 4%; thymus, 5 +-6% vs 98 + 1%; and spleen, 18 + 6% vs 94 _+ 1%). In fact, the effidency of donor-origin cell repopulation by 107 PBL from rhlb7-treated donors was as good as that achieved by 10 + normal BM cells. Mice transplanted with 106 PBL from rhlb7-treated donors at 6 mo exhibited higher variability in terms of the percentage of donor cells for various organs (BM, 33 _+ 51%; thymus, 41 _+ 51%; spleen, 51 + 36%), but those mean percentages tended to be much higher than those attained by 107 PBL from normal donors. These results show that administration of rhIL-7 can mobilize progenitor and stem ceils required for both short-and long-term repopulation. Successful repopulation with donor ceils was dependent on the number of PBL transplanted, with a dose of 10 + from rhlL-7-treated donors being borderline for complete survival and repopulation of irradiated recipients, whereas 107 PBL or 106 BM cells were able to efficiently repopulate recipient mice. Interestingly, 107 PBL from control donors also were able to rescue some mice for 6 too, however ultimately repopulation was largely of host origin. Thus, normal peripheral blood contains adequate numbers of shortterm repopulating ceils (STRC) (18) to allow survival of irradiated mice; however, there are few long-term repopulating cells (LTRC), which predominantly contribute to both 3-and 6-mo survival. The frequency of STRCs in normal PBL must be low since 106 PBL from control mice failed to rescue any recipients. In fact, as shown in Fig. 1 (B) , there were only 4 _ 1 CFU-Ss and 4 _+ 2 CFU-St2 per 2 x 105 cells detected in the blood of control mice, whereas the rhlL-7-treated mice showed a significant increase (p <0.001) in the frequency of these progenitors (e.g., 14 _ 2 CFU-Ss and 13 _ 1 CFU-S~). This increase might contribute to the observation that 10-fold fewer PBL from IL-7-treated mice were able to fully rescue mice compared with PBL from normal mice. Although 106 PBL from rhlb7-treated donors and 107 PBL from control mice were able to rescue the lethally irradiated recipients, only PBL from mice treated with rhlb7 could successfully repopulate various organs with donorderived cells, further suggesting that PBL from control mice contain STRCs supporting early BM recovery, followed by repopulation with host-originated LTRCs that survived irradiation. In contrast, PBL from rhlL-7-treated donors provide both STRCs for initial recovery and LT1LCs that sustain long-term hematopoiesis. This is further emphasized by the data shown in Fig. 3 , inset table, where complete trilineage (T and B cell, and myelomonocytic cell) reconstitution is demonstrated in various organs. A similar trend also was observed by 3 mo (data not shown).
Interestingly, BM cells from rhlL-7-treated mice were almost equal to BM cells from control mice in repopulating activity. Our previously published results demonstrated that mature progenitors were reduced in BM from mice treated with rhlL-7 (CFU-C and CFU-GEMM) (6, 7) , suggesting that the ability of such BM to repopulate lethally irradiated mice might also be diminished. The data presented herein suggest that at least some threshold number of short-and long-term repopulating cells are retained in BM from rhlL-7-treated mice. This is in agreement with previous data that various progenitors detected by different colony-forming assays do not always equate to an ability to reconstitute short-and long-term hematopoiesis in irradiated mice (19) .
Several hematopoietic growth factors (HGF) have been studied as mobilizing agents, alone or in combination, in preclinical studies or clinical trials (e.g., G-CSF, GM-CSF, IL-3/Epo, IL-1, stem cell factor [SCF], IL-11) (4, 20) . Some HGFs have their activity restricted to myelopoiesis whereas others stimulate lymphopoiesis and myelopoiesis (21) . To date, ID7 had been reported to primarily stimulate lymphopoiesis (13, 22) , with a pronounced increase in the number of mature T lymphocytes, particularly CD8 + T cells, as well as T cell-mediated responses (13) . Additionally, we found that II.-7 also influenced early myeloid progenitors (7) . In this regard, IL-7 has been shown to synergize with GM-CSF and SCF to enhance in vitro myeloid colony formation of LinSca-1 + routine BM progenitor cells (9) .
In summary, rhlb7 has novel functions in vivo because of its ability to mobilize myeloid stem cells/progenitors from the BM to periphery, its ability to accelerate regeneration of donor B and T lineages after transfer to irradiated hosts (Boerman, O. C., T. A. Gregorio, K. Grzegorzewski, C. R. Faltynek, R. L. Wiltrout, and K. L. Komschlies, manuscript submitted for publication), and documented potent effects on lymphocyte proliferation and T cell function (13) . The mechanism of action for the stem cell mobilizing effects of rhlb7, as well as those for G-CSF and SCF, remains unknown and may be at least partially indirect through induction of other mobilizing cytokines (23) or through inhibition of negative regulators of hematopoiesis (24) . A comparison of the mobilizing ability of rhlL-7 with other cytokines and its ability to synergize with other stem cell mobilizers is in progress. Ultimately, rhIL-7 may prove useful for increasing the effidency of stem cell mobilization into the peripheral blood for gene transfer studies, and for autologous or allogeneic stem cell transplants.
